Skip to main navigation
  • Contact Us
Xen 01
  • About Us
    • Management
    • Partnering
    • Board of Directors
  • Pipeline
    • Vudalimab (PD-1 x CTLA-4)
    • Plamotamab (CD20 x CD3)
    • XmAb104 (PD-1 x ICOS)
    • XmAb564 (IL-2-Fc)
    • XmAb819 (ENPP3 x CD3)
  • Technology
    • Bispecific Fc Domains
    • Cytotoxic Fc Domains
    • Immune Inhibitor Fc Domains
    • Xtend Fc Domains
    • Publications
  • Clinical Trials
    • Expanded Access Policy
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Corporate Responsibility
    • Financials & Filings
      • SEC Filings
      • Annual Reports
    • Analyst Coverage
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
    • Investor FAQs
    • Contact Us
    • Email Alerts
  • Careers
    • Opportunities

You are here:
Home / Investors / SC 13G/A

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Corporate Responsibility
  • Financials & Filings
  • Analyst Coverage
  • Stock Information
  • Investor FAQs
  • Contact Us
  • Email Alerts

Tools

Shareholder Tools

  • Snaphot
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter
  • RSS

SEC Filing Details

Document Details

Form
SC 13G/A
Filing Date
Dec 8, 2022
Document Date
Dec 8, 2022
Form Description
An amendment to the SC 13G filing
Filing Group
Other
Company
Xencor, Inc.
Issuer
Xencor Inc

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
Xencor © Copyright 2023 | Privacy Policy
Scroll to top